YOLFTbeta
Beijing Chunlizhengda Medical Instruments Co Ltd

Beijing Chunlizhengda Medical Instruments Co Ltd

688236 · SHG · Healthcare / Medical Devices

13.05CNY-0.19 (-1.44%)

Price History

Full chart

Market Stats

Previous Close13.24
Open13.25
Day Range13.03 – 13.48
52-Week Range13.11 – 29.13
Volume2.13M
Market Cap5.44B
P/E (TTM)19.76
Forward P/E0.00
EPS0.72
Dividend Yield2.87%
Beta-0.25
50-Day Avg14.31
200-Day Avg18.24

About

Beijing Chunlizhengda Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China and internationally. The company offers orthopedic medical devices and tissue repair products, including spine, trauma, joint, sports medicine, and bone repair material implants; surgical instrumentation products; platelet-rich plasma preparation kits; and closed wound negative pressure drainage kits. It also provides surgical robots; joint, spinal, sports medicine, trauma, oral care, and endoscopic products; orthopedic power products; and platelet-rich plasma preparation system products, as well as alloy materials and surgical powering equipment. The company exports its products to approximately 68 countries. The company was formerly known as Chunli Limited and changed its name to Beijing Chunlizhengda Medical Instruments Co., Ltd. in September 2010. Beijing Chunlizhengda Medical Instruments Co., Ltd. was incorporated in 1998 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMs. Wenling Shi
  • Employees841
  • HeadquartersNo. 10, Xinmi Xi Er Road, Beijing, China, China
  • Websitehttps://www.clzd.com

Leadership

  • Ms. Wenling ShiExecutive Chair of the Board · b. 1998
  • Mr. Chunsheng ShiGeneral Manager · b. 1985
  • Ms. Shujun YueDeputy GM & Executive Director · b. 1971
  • Mr. Chunbao ShiChief Engineer & Executive Director · b. 1970
  • Mr. Feng Bao XieDeputy Chief Engineer, Secretary of the Board & Executive Director · b. 1982
  • Ms. Hongyue LuCFO & Accounting Supervisor · b. 1993
  • Mr. Xiwang LiDeputy General Manager · b. 1985

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue98.09M110.55M134.53M177.37M207.93M300.32M497.93M855.33M937.69M1.11B1.20B1.21B805.86M1.04B
Growth (%)-+12.69%+21.70%+31.84%+17.23%+44.43%+65.80%+71.78%+9.63%+18.18%+8.43%+0.58%-33.32%+29.52%
Cost of Revenue27.54M30.47M34.96M55.28M48.88M86.96M182.02M270.76M257.09M264.11M301.53M353.34M289.37M355.13M
Gross Profit70.56M80.07M99.58M122.09M159.04M213.36M315.91M584.57M680.60M844.03M900.08M855.18M516.49M1.04B
Gross Margin71.93%72.44%74.02%68.83%76.49%71.04%63.45%68.34%72.58%76.17%74.91%70.76%64.09%100.00%
Operating Expense34.41M42.37M57.33M78.59M88.23M134.38M196.42M311.03M350.50M476.43M571.17M549.21M385.77M742.01M
Operating Income36.15M37.71M42.25M43.50M70.81M78.98M119.49M273.54M330.10M367.59M328.91M305.98M130.71M301.75M
Operating Margin36.85%34.11%31.40%24.52%34.06%26.30%24.00%31.98%35.20%33.17%27.37%25.32%16.22%28.91%
EBITDA40.31M42.07M47.04M48.45M79.81M85.39M126.96M284.92M344.93M384.18M365.26M339.52M169.04M337.63M
EBITDA Margin41.10%38.05%34.97%27.31%38.38%28.43%25.50%33.31%36.79%34.67%30.40%28.09%20.98%32.35%
Net Income31.94M32.67M37.03M37.87M63.44M68.28M105.65M236.76M283.37M322.36M307.72M277.82M124.99M272.12M
Net Income Margin32.56%29.55%27.53%21.35%30.51%22.74%21.22%27.68%30.22%29.09%25.61%22.99%15.51%26.07%
R&D4.87M4.81M8.00M13.32M14.28M21.22M35.45M57.75M72.60M104.84M162.34M157.45M133.10M118.50M
R&D as % of Total Revenue4.97%4.35%5.95%7.51%6.87%7.06%7.12%6.75%7.74%9.46%13.51%13.03%16.52%11.35%
Interest Expense30.98K46.18K67.73K95.22K64.58K86.54K96.04K124.68K141.60K256.55K250.06K364.86K1.03M39.15K
Interest Expense % of Total Revenue0.03%0.04%0.05%0.05%0.03%0.03%0.02%0.01%0.02%0.02%0.02%0.03%0.13%0.00%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets187.51M200.63M239.86M478.04M540.13M633.66M814.74M1.21B1.54B3.00B3.41B3.65B3.47B3.66B
Total Liabilities14.34M20.74M33.94M54.49M59.22M95.19M186.60M402.72M460.41M530.58M690.07M770.33M644.39M-2.99B
Total Equity167.22M179.89M205.92M423.56M480.91M538.47M628.14M806.59M1.08B2.47B2.72B2.88B2.82B2.99B
Cash50.51K65.86M63.56M239.07M297.29M371.62M414.91M464.18M690.12M1.74B957.19M1.27B1.14B1.41B
Total Debt--------1.85M1.23M1.31M1.75M866.44K-
Net Debt-50.51K-65.86M-63.56M-239.07M-297.29M-371.62M-414.91M-464.18M-688.26M-1.74B-955.88M-1.26B-1.14B-

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow28.83M28.20M24.27M-510.60K64.95M89.83M108.51M231.54M260.68M164.79M41.01M511.71M-1.90M-
Investing Cash Flow-298.82K-1.24M-9.54M-17.67M1.70M-3.49M-48.21M-125.50M-21.54M-190.35M-762.61M-81.56M55.84M-
Financing Cash Flow-12.00M-22.36M-17.03M187.67M-6.09M-10.72M-15.98M-56.81M-11.88M1.07B-59.04M-121.33M-183.14M-
Capital Expenditure6.41M6.70M11.77M26.58M8.36M8.98M52.12M132.41M24.00M199.41M24.90M33.24M49.17M59.13M
Free Cash Flow22.42M21.50M12.50M-27.09M56.59M80.85M56.39M99.13M236.68M-34.62M16.10M478.47M-51.07M345.71M
Dividends Paid12.00M20.00M11.00M6.09M6.09M10.72M15.98M56.81M10.38M-49.96M120.06M170.53M18.73M
FCF to OCF77.76%76.23%51.51%5306.28%87.13%90.00%51.97%42.81%90.79%-21.01%39.27%93.50%2688.60%-
Dividend Paid to FCF53.53%93.03%87.97%-22.47%10.76%13.26%28.34%57.31%4.38%-310.23%25.09%-333.91%5.42%

Earnings

Report DateMar 29, 2022Apr 28, 2022Aug 25, 2022Oct 26, 2022Apr 27, 2023
EPS Estimate-----
EPS Actual0.310.190.220.140.26
Surprise-----
TimingPre-marketAfter-hoursAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap5.44B
Enterprise Value2.61B
Trailing P/E19.76
Forward P/E0.00
Price / Sales5.58
Price / Book1.87
EPS0.72
Book Value7.98
Revenue (TTM)975.27M
Gross Profit (TTM)616.46M
EBITDA323.85M
Profit Margin28.51%
Operating Margin30.86%
Return on Equity9.33%
Return on Assets5.04%
Shares Outstanding287.05M
Shares Float157.76M
Beta-0.25
Dividend Yield2.87%
Dividend Rate0.41
Payout Ratio56.81%

Dividends

20262×
0.15Jul 3, 20260.21Jan 9, 2026
20251×
0.05Aug 1, 2025
20242×
0.08Nov 25, 20240.36Aug 5, 2024
20231×
0.31Jul 28, 2023
20221×
0.13Jun 21, 2022